title: Loss of ovarian function promotes angiogenesis in human ovarian carcinoma.
abstract: We show here that elevated levels of gonadotropins (luteinizing hormone and follicle stimulating hormone), as found in menopause or after ovariectomy, promote growth of human ovarian carcinoma by induction of tumor angiogenesis. Human epithelial ovarian cancer tumors progressed faster in ovariectomized mice. This induced growth could be attributed to the elevated levels of gonadotropins associated with loss of ovarian function because direct administration of gonadotropins also was effective in promoting tumor progression in vivo. On the other hand, gonadotropins had no direct effect on the proliferation of human ovarian cancer cells in vitro. Using MRI, we demonstrated that ovariectomy significantly (P < 0.02) induces neovascularization of human ovarian carcinoma spheroids implanted in nude mice. Moreover, conditioned medium of gonadotropin-treated human ovarian carcinoma cells showed increased mitogenic activity to bovine endothelial cells, and this activity could be blocked by neutralizing antibodies against luteinizing hormone and against vascular endothelial growth factor. Accordingly, gonadotropin stimulation resulted in a dose-dependent-induced expression of vascular endothelial growth factor in monolayer culture as well as in the outer proliferating cells of human ovarian cancer spheroids. These results demonstrate the significance of the elevated levels of gonadotropins, as found in menopause and in all ovarian cancer patients, on the progression of ovarian cancer and could explain the protective effect of estrogen replacement therapy. Based on these results, we suggest that hormonal therapy aimed at lowering the circulating levels of gonadotropins may possibly prolong remission in ovarian cancer by extending tumor dormancy.
authors.affiliation: Department of Biological Regulation, The Weizmann Institute of Science, Rehovot, Israel.
authors.forename: Y S
authors.initials: YS
authors.lastname: Schiffenbauer
authors.forename: R
authors.initials: R
authors.lastname: Abramovitch
authors.forename: G
authors.initials: G
authors.lastname: Meir
authors.forename: N
authors.initials: N
authors.lastname: Nevo
authors.forename: M
authors.initials: M
authors.lastname: Holzinger
authors.forename: A
authors.initials: A
authors.lastname: Itin
authors.forename: E
authors.initials: E
authors.lastname: Keshet
authors.forename: M
authors.initials: M
authors.lastname: Neeman
mesh_terms: D000818:Animals; D016228:Endothelial Growth Factors / Q000235:genetics; D005260:Female; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D006801:Humans; D017403:In Situ Hybridization; D007986:Luteinizing Hormone / Q000378:metabolism; D008222:Lymphokines / Q000235:genetics; D008279:Magnetic Resonance Imaging; D008593:Menopause; D051379:Mice; D008819:Mice, Nude; D009389:Neovascularization, Pathologic / Q000503:physiopathology*; D010051:Ovarian Neoplasms / Q000098:blood supply* / Q000503:physiopathology; D010052:Ovariectomy; D010053:Ovary / Q000503:physiopathology*; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D014407:Tumor Cells, Cultured; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: D016228:Endothelial Growth Factors; D008222:Lymphokines; D012333:RNA, Messenger; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone